These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 19410661

  • 1. Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.
    Sundstedt A, Celander M, Ohman MW, Forsberg G, Hedlund G.
    Int Immunopharmacol; 2009 Aug; 9(9):1063-70. PubMed ID: 19410661
    [Abstract] [Full Text] [Related]

  • 2. Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects.
    Sundstedt A, Celander M, Hedlund G.
    Int Immunopharmacol; 2008 Mar; 8(3):442-52. PubMed ID: 18279798
    [Abstract] [Full Text] [Related]

  • 3. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A, Celander M, Eriksson H, Törngren M, Hedlund G.
    J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
    [Abstract] [Full Text] [Related]

  • 4. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
    Wang Q, Yu H, Zhang L, Ju D, Pan J, Xia D, Yao H, Zhang W, Wang J, Cao X.
    J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740
    [Abstract] [Full Text] [Related]

  • 5. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.
    Wang Q, Yu H, Ju DW, He L, Pan JP, Xia DJ, Zhang LH, Cao X.
    Gene Ther; 2001 Apr; 8(7):542-50. PubMed ID: 11319621
    [Abstract] [Full Text] [Related]

  • 6. Immune response during tumor therapy with antibody-superantigen fusion proteins.
    Rosendahl A, Hansson J, Sundstedt A, Kalland T, Dohlsten M.
    Int J Cancer; 1996 Sep 27; 68(1):109-13. PubMed ID: 8895549
    [Abstract] [Full Text] [Related]

  • 7. Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo.
    Dohlsten M, Hansson J, Ohlsson L, Litton M, Kalland T.
    Proc Natl Acad Sci U S A; 1995 Oct 10; 92(21):9791-5. PubMed ID: 7568219
    [Abstract] [Full Text] [Related]

  • 8. The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens.
    Litton MJ, Dohlsten M, Rosendahl A, Ohlsson L, Søgaard M, Andersson J, Andersson U.
    Br J Cancer; 1999 Sep 10; 81(2):359-66. PubMed ID: 10496366
    [Abstract] [Full Text] [Related]

  • 9. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens.
    Rosendahl A, Kristensson K, Hansson J, Riesbeck K, Kalland T, Dohlsten M.
    J Immunol; 1998 Jun 01; 160(11):5309-13. PubMed ID: 9605129
    [Abstract] [Full Text] [Related]

  • 10. Tumor therapy with an antibody-targeted superantigen generates a dichotomy between local and systemic immune responses.
    Litton MJ, Dohlsten M, Hansson J, Rosendahl A, Ohlsson L, Kalland T, Andersson J, Andersson U.
    Am J Pathol; 1997 May 01; 150(5):1607-18. PubMed ID: 9137087
    [Abstract] [Full Text] [Related]

  • 11. Naptumomab estafenatox, an engineered antibody-superantigen fusion protein with low toxicity and reduced antigenicity.
    Forsberg G, Skartved NJ, Wallén-Ohman M, Nyhlén HC, Behm K, Hedlund G, Nederman T.
    J Immunother; 2010 Jun 01; 33(5):492-9. PubMed ID: 20463598
    [Abstract] [Full Text] [Related]

  • 12. Treatment with tumor-reactive Fab-IL-2 and Fab-staphylococcal enterotoxin A fusion proteins leads to sustained T cell activation, and long-term survival of mice with established tumors.
    Søgaard M, Ohlsson L, Kristensson K, Rosendahl A, Sjoberg A, Forsberg G, Kalland T, Dohlsten M.
    Int J Oncol; 1999 Nov 01; 15(5):873-82. PubMed ID: 10536168
    [Abstract] [Full Text] [Related]

  • 13. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies.
    Liu R, Jiang W, Yang M, Guo H, Zhang Y, Wang J, Zhu H, Shi R, Fan D, Yang C, Zhu Z, Xie Y, Xiong D.
    J Immunother; 2010 Jun 01; 33(5):500-9. PubMed ID: 20463597
    [Abstract] [Full Text] [Related]

  • 14. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B, VanRoey M, Wang C, Chen TH, Korman A, Jooss K.
    Clin Cancer Res; 2009 Mar 01; 15(5):1623-34. PubMed ID: 19208793
    [Abstract] [Full Text] [Related]

  • 15. A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.
    Gidlöf C, Dohlsten M, Lando P, Kalland T, Sundström C, Tötterman TH.
    Blood; 1997 Mar 15; 89(6):2089-97. PubMed ID: 9058731
    [Abstract] [Full Text] [Related]

  • 16. The treatment and prevention of mouse melanoma with an oral DNA vaccine carried by attenuated Salmonella typhimurium.
    Zhu X, Cai J, Huang J, Jiang X, Ren D.
    J Immunother; 2010 Jun 15; 33(5):453-60. PubMed ID: 20463603
    [Abstract] [Full Text] [Related]

  • 17. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy.
    Dohlsten M, Abrahmsén L, Björk P, Lando PA, Hedlund G, Forsberg G, Brodin T, Gascoigne NR, Förberg C, Lind P.
    Proc Natl Acad Sci U S A; 1994 Sep 13; 91(19):8945-9. PubMed ID: 8090750
    [Abstract] [Full Text] [Related]

  • 18. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
    Winkelhake JL, Stampfl S, Zimmerman RJ.
    Cancer Res; 1987 Aug 01; 47(15):3948-53. PubMed ID: 3496953
    [Abstract] [Full Text] [Related]

  • 19. Long-term survival and complete cures of B16 melanoma-carrying animals after therapy with tumor-targeted IL-2 and SEA.
    Rosendahl A, Kristensson K, Carlsson M, Skartved NJ, Riesbeck K, Søgaard M, Dohlsten M.
    Int J Cancer; 1999 Mar 31; 81(1):156-63. PubMed ID: 10077167
    [Abstract] [Full Text] [Related]

  • 20. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR, Holst PJ, Pircher H, Christensen JP, Thomsen AR.
    Eur J Immunol; 2009 Oct 31; 39(10):2725-36. PubMed ID: 19637230
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.